BR112021018994A2 - Formulação de combinação tripla de baixa dose - Google Patents

Formulação de combinação tripla de baixa dose

Info

Publication number
BR112021018994A2
BR112021018994A2 BR112021018994A BR112021018994A BR112021018994A2 BR 112021018994 A2 BR112021018994 A2 BR 112021018994A2 BR 112021018994 A BR112021018994 A BR 112021018994A BR 112021018994 A BR112021018994 A BR 112021018994A BR 112021018994 A2 BR112021018994 A2 BR 112021018994A2
Authority
BR
Brazil
Prior art keywords
inhibitor
combination formulation
triple combination
low dose
dose
Prior art date
Application number
BR112021018994A
Other languages
English (en)
Inventor
Anthony Rodgers
Stephen Macmahon
Original Assignee
The George Inst For Global Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The George Inst For Global Health filed Critical The George Inst For Global Health
Publication of BR112021018994A2 publication Critical patent/BR112021018994A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

formulação de combinação tripla de baixa dose. são fornecidas nesse documento composições farmacêuticas que são úteis para o tratamento de diabetes e condições, doenças e distúrbios associados. as composições compreendem a) um inibidor da dipeptidil peptidase iv (dppiv), como a sitagliptina, b) um inibidor do transporte de sódio-glicose do subtipo 2 (sglt2), como dapagliflozina ou empagliflozina e c) uma biguanida, como a metformina. o inibidor dppiv, o inibidor sglt2 e a biguanida estão em uma dose que é cerca de 20-75% da menor dose terapêutica para diabetes.
BR112021018994A 2019-03-25 2020-03-25 Formulação de combinação tripla de baixa dose BR112021018994A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/364,063 US11033544B2 (en) 2019-03-25 2019-03-25 Low-dose triple combination formulation
PCT/IB2020/000214 WO2020194052A1 (en) 2019-03-25 2020-03-25 Low-dose triple combination formulation

Publications (1)

Publication Number Publication Date
BR112021018994A2 true BR112021018994A2 (pt) 2022-02-08

Family

ID=72606637

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021018994A BR112021018994A2 (pt) 2019-03-25 2020-03-25 Formulação de combinação tripla de baixa dose

Country Status (11)

Country Link
US (5) US11033544B2 (pt)
EP (1) EP3946344A4 (pt)
JP (1) JP2022529208A (pt)
KR (1) KR20220004027A (pt)
CN (1) CN113924096A (pt)
AU (1) AU2020247542A1 (pt)
BR (1) BR112021018994A2 (pt)
CA (1) CA3134800A1 (pt)
MX (1) MX2021011746A (pt)
TW (1) TW202102209A (pt)
WO (1) WO2020194052A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033544B2 (en) * 2019-03-25 2021-06-15 The George Institute for Global Health Low-dose triple combination formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065809A1 (es) * 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
RS60438B1 (sr) * 2009-02-13 2020-07-31 Boehringer Ingelheim Int Farmaceutska kompozicija koja sadrži sglt2 inhibitor, dpp-iv inhibitor i opciono drugo antidijabetičko sredstvo i njihove upotrebe
EP3142661B1 (en) 2014-05-16 2021-10-06 Astrazeneca AB Method for suppressing glucagon secretion of an sglt2 inhibitor
WO2016040462A2 (en) * 2014-09-09 2016-03-17 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US11033544B2 (en) * 2019-03-25 2021-06-15 The George Institute for Global Health Low-dose triple combination formulation

Also Published As

Publication number Publication date
MX2021011746A (es) 2021-10-22
US11033544B2 (en) 2021-06-15
CN113924096A (zh) 2022-01-11
WO2020194052A1 (en) 2020-10-01
US20220226316A1 (en) 2022-07-21
US20220226317A1 (en) 2022-07-21
US20220226315A1 (en) 2022-07-21
US20210260056A1 (en) 2021-08-26
EP3946344A1 (en) 2022-02-09
US20200306246A1 (en) 2020-10-01
EP3946344A4 (en) 2022-12-28
AU2020247542A1 (en) 2021-11-11
KR20220004027A (ko) 2022-01-11
JP2022529208A (ja) 2022-06-20
CA3134800A1 (en) 2020-10-01
TW202102209A (zh) 2021-01-16

Similar Documents

Publication Publication Date Title
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CU20070203A7 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
SV2010003491A (es) 2- anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112021018973A2 (pt) Formulação de combinação tripla de baixa dose
CO2022011728A2 (es) Composiciones y usos de glp-1
ZA202210355B (en) Compositions and therapeutic uses of cannabidiol
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
RU2017120184A (ru) Лекарства для замедления течения болезни паркинсона
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
ECSP23096498A (es) Restos de administración terapéutica novedosos y usos de estos
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
BR112023001143A2 (pt) Conjugado, composto, composição farmacêutica, métodos para tratar uma doença e reduzir o nível de uma proteína brm alvo em um indivíduo
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
BR112021018994A2 (pt) Formulação de combinação tripla de baixa dose
AR062779A1 (es) Tratamiento de la esclerosis multiple (em)